IceCure Medical Ltd., a company specializing in minimally-invasive cryoablation technology for tumor destruction, has filed a prospectus related to its rights offering with the U.S. Securities and Exchange Commission. The offering, which was declared effective on July 9, 2025, allows holders of the company's ordinary shares as of the record date to purchase up to a total of 10,000,000 units. Shareholders were distributed non-transferable subscription rights at no charge. The prospectus provides detailed information about the offering and is available on the SEC's website, while inquiries can be directed to Broadridge Corporate Issuer Solutions, LLC, the appointed Information Agent.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。